Literature DB >> 11960492

Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.

Julia M Adam1, D Jonathan Bennett, Anton Bom, John K Clark, Helen Feilden, Edward J Hutchinson, Ronald Palin, Alan Prosser, David C Rees, Georgina M Rosair, Donald Stevenson, Gary J Tarver, Ming-Qiang Zhang.   

Abstract

A series of mono- and per-6-substituted cyclodextrin derivatives were synthesized as synthetic receptors (or host molecules) of rocuronium bromide, the most widely used neuromuscular blocker in anaesthesia. By forming host-guest complexes with rocuronium, these cyclodextrin derivatives reverse the muscle relaxation induced by rocuronium in vitro and in vivo and therefore can be used as reversal agents of the neuromuscular blocker to assist rapid recovery of patients after surgery. Because this supramolecular mechanism of action does not involve direct interaction with the cholinergic system, the reversal by these compounds, e.g., compound 14 (Org 25969), is not accompanied by cardiovascular side effects usually attendant with acetylcholinesterase inhibitors such as neostigmine. The structure-activity relationships are consistent with this supramolecular mechanism of action and are discussed herein. These include the effects of binding cavity size and hydrophobic and electrostatic interaction on the reversal activities of these compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960492     DOI: 10.1021/jm011107f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  Slow actions of neuroactive steroids at GABAA receptors.

Authors:  Hong-Jin Shu; Lawrence N Eisenman; Deepani Jinadasa; Douglas F Covey; Charles F Zorumski; Steven Mennerick
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

2.  Effects of sugammadex on immunoreactivity of calcineurin in rat testes cells after neuromuscular block: a pilot study.

Authors:  Yıldıray Kalkan; Levent Tümkaya; Habib Bostan; Yakup Tomak; Adnan Yılmaz
Journal:  J Mol Histol       Date:  2011-12-29       Impact factor: 2.611

3.  Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex.

Authors:  Pieter-Jan de Kam; Michiel W van den Heuvel; Peter Grobara; Alex Zwiers; Jean-Luc Jadoul; Erik de Clerck; Steven Ramael; Pierre A M Peeters
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

4.  Access of inhibitory neurosteroids to the NMDA receptor.

Authors:  Jirina Borovska; Vojtech Vyklicky; Eva Stastna; Vojtech Kapras; Barbora Slavikova; Martin Horak; Hana Chodounska; Ladislav Vyklicky
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Parenteral delivery of HPβCD: effects on drug-HSA binding.

Authors:  Sergey V Kurkov; Thorsteinn Loftsson; Martin Messner; Donna Madden
Journal:  AAPS PharmSciTech       Date:  2010-07-24       Impact factor: 3.246

6.  Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.

Authors:  Pieter-Jan de Kam; Jacqueline van Kuijk; Marita Prohn; Torben Thomsen; Pierre Peeters
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia.

Authors:  Pieter-Jan de Kam; Peter Grobara; Justin Dennie; Guy Cammu; Steven Ramael; Marjan L F Jagt-Smook; Michiel W van den Heuvel; Rob J W Berg; Pierre A M Peeters
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

8.  Developmentally regulated neurosteroid synthesis enhances GABAergic neurotransmission in mouse thalamocortical neurones.

Authors:  Adam R Brown; Murray B Herd; Delia Belelli; Jeremy J Lambert
Journal:  J Physiol       Date:  2014-12-03       Impact factor: 5.182

Review 9.  Sugammadex: a review of its use in anaesthetic practice.

Authors:  Lily P H Yang; Susan J Keam
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.

Authors:  Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.